ConductScience.org, home

Paper41814014

Immunophenotypic changes following menin inhibition in acute myeloid leukemia.

Loghavi S and 24 others. Leukemia, 2026. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Immunophenotypic changes following menin inhibition in acute myeloid leukemia. Papers, record 41814014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41814014

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
PubMed
Journal
Leukemia
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-08-13
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Proto-Oncogene ProteinsMajor topic
Humans
Immunophenotyping
Nucleophosmin
Female
Middle Aged
Male
Aged
Adult
Neoplasm, Residual
Flow Cytometry
Prognosis
Aged, 80 and over
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Faculty Scholar AwardUT | University of Texas MD Anderson Cancer Center (MD Anderson)PubMed

Source PubMed

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
211113197Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.Mol Cell Biol2001https://conductscience.org/library/papers/11113197PubMed
3347245632021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.Blood2021https://conductscience.org/library/papers/34724563PubMed
430803991Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.Blood2019https://conductscience.org/library/papers/30803991PubMed
530171025Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.Haematologica2019https://conductscience.org/library/papers/30171025PubMed
635618837A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.Nat Med2022https://conductscience.org/library/papers/35618837PubMed
729128069How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?Clin Lab Med2017https://conductscience.org/library/papers/29128069PubMed
825817203Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.Cancer Cell2015https://conductscience.org/library/papers/25817203PubMed
939362248Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.Lancet Oncol2024https://conductscience.org/library/papers/39362248PubMed
1032001657Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.Science2020https://conductscience.org/library/papers/32001657PubMed
1140409258Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.Cell Stem Cell2025https://conductscience.org/library/papers/40409258PubMed
1231821784A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.Cancer Cell2019https://conductscience.org/library/papers/31821784PubMed
1340522873Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort.Arch Pathol Lab Med2025https://conductscience.org/library/papers/40522873PubMed
1437605812Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection.Cytometry B Clin Cytom2023https://conductscience.org/library/papers/37605812PubMed
1531974170Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.Cancer Discov2020https://conductscience.org/library/papers/31974170PubMed
1633618432Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.Br J Haematol2021https://conductscience.org/library/papers/33618432PubMed
1737019990The KMT2A recombinome of acute leukemias in 2023.Leukemia2023https://conductscience.org/library/papers/37019990PubMed
1828588020Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood2017https://conductscience.org/library/papers/28588020PubMed
1940332046Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Blood2025https://conductscience.org/library/papers/40332046PubMed
2039121437Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).J Clin Oncol2025https://conductscience.org/library/papers/39121437PubMed

See all 28 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn Papers
42122138Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.Cancers (Basel)2026https://conductscience.org/library/papers/42122138

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
KMT2A4297PubTator's text mininghttps://conductscience.org/library/genes/4297NCBI Gene
MEN14221PubTator's text mininghttps://conductscience.org/library/genes/4221NCBI Gene
NPM14869PubTator's text mininghttps://conductscience.org/library/genes/4869NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41814014

GET https://conductscience.org/api/papers/v1/41814014/authors?page=2